Deutsche Bank
QNCX icon

Deutsche Bank’s Quince Therapeutics QNCX Stock Holding History

Deutsche Bank’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-79
Closed -$97K – 4285
2022
Q1 		$97K Buy
79
+4
+5% +$5.44K ﹤0.01% 3591
2021
Q4 		$188K Sell
75
-7
-9% -$42.7K ﹤0.01% 3416
2021
Q3 		$1.5M Buy
82
+19
+30% +$302K ﹤0.01% 2337
2021
Q2 		$664K Buy
63
+9
+17% +$75.5K ﹤0.01% 3042
2021
Q1 		$387K Sell
54
-10
-16% -$72K ﹤0.01% 3259
2020
Q4 		$354K Buy
64
+16
+33% +$142K ﹤0.01% 3134
2020
Q3 		$479K Buy
48
+3
+7% +$27.3K ﹤0.01% 2663
2020
Q2 		$413K Buy
45
+25
+125% +$229K ﹤0.01% 2749
2020
Q1 		$181K Sell
20
-1
-5% -$9.87K ﹤0.01% 2995
2019
Q4 		$234K Buy
21
+17
+425% +$103K ﹤0.01% 3124
2019
Q3 		$19K Sell
4
-7
-64% -$43.1K ﹤0.01% 4344
2019
Q2 		$92K Buy
+11
New +$65.7K ﹤0.01% 4250

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Deutsche Bank's QNCX Position: Q2 2022 in Review

Deutsche Bank sold out of Quince Therapeutics (QNCX) in Q2 2022, closing a stake of 79 shares — an estimated $97K sold.

Deutsche Bank first reported a position in QNCX in Q2 2019 and held it in 12 quarters. The position peaked at $1.5M in Q3 2021. 66 funds tracked by Wall St. Rank hold QNCX as of Q2 2022.

  • Deutsche Bank reported no remaining Quince Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Deutsche Bank sold 79 Quince Therapeutics shares in Q2 2022, an estimated $97K.
  • Deutsche Bank first reported a position in Quince Therapeutics in Q2 2019 and held it in 12 quarters.
  • Deutsche Bank's Quince Therapeutics position peaked at $1.5M in Q3 2021.
  • 66 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2022.

Based on Deutsche Bank's 13F filing for Q2 2022, filed 11 Aug 2022.